Becton, Dickinson and Company (BD) has reported revenues of $5.1bn, representing a 7.3% increase for the fourth quarter (Q4) of 2021 compared to $4.7bn in the prior-year quarter.

For the full fiscal year 2021, the company reported $20.2bn in revenues, an 18.3% increase, on a reported basis, as against $17.1bn last year.

BD’s Medical business unit reported $2.53bn in revenue, a 9.2% increase from $2.32bn reported in the same quarter last year, while the revenues from the company’s Life Sciences segment increased by 2.9% to $1.53bn during the period.

Revenues in the Interventional segment stood at $1.07bn, an increase of 9.5% from $978m reported last year.

Additionally, BD repurchased three million shares for a total consideration of $750m during Q4.

Recently, the company has also launched products that include the BD COR System and BD FACSymphony A1 Cell Analyzer.

The company received emergency use authorization (EUA) for the BD Veritor At-Home COVID-19 Test from the US Food and Drug Administration (FDA) as well as 510(k) clearance for the Rotarex Rotational Excisional Atherectomy System.

BD chairman, CEO and president Tom Polen said: “Our strong performance in fiscal 2021 was driven by the extraordinary efforts of our global team and demonstrates the resilience of BD’s portfolio in even the most uncertain health care environments.

“We also took a number of critical steps this year to lay the foundation for the next phase of our growth, which included strengthening our balance sheet and cash flows, increasing our investments into higher-growth spaces, and stepping up our pace of tuck-in M&A activity.”

Next year, the company hopes to generate $19.3bn to $19.5bn in revenues.

Last month, BD and the US Biomedical Advanced Research and Development Authority collaborated for the development of a range of combination diagnostic tests for Covid-19.